{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:05:55Z","timestamp":1783721155392,"version":"3.55.0"},"reference-count":25,"publisher":"American Veterinary Medical Association (AVMA)","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>OBJECTIVE<\/jats:title>\n<jats:p>To determine the clinical significance of performing repeated postchemotherapy CBC for cancer-bearing dogs receiving \u2265 4 carboplatin treatments. The secondary aim was to identify risk factors associated with cumulative carboplatin-induced neutropenia in those dogs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>ANIMALS<\/jats:title>\n<jats:p>40 client-owned dogs diagnosed with cancer.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>METHODS<\/jats:title>\n<jats:p>A retrospective study using medical records from a single academic institution during 2012 to 2023. Dogs that received \u2265 4 doses of carboplatin with pre- and postchemotherapy CBCs available were included. Signalment and possible risk factors were recorded. Veterinary Cooperative Oncology Group\u2013Common Terminology Criteria for Adverse Events was used for neutropenia grading.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>RESULTS<\/jats:title>\n<jats:p>40 dogs met the inclusion criteria, with a total of 206 prechemotherapy and 188 postchemotherapy CBC results available. The median carboplatin dosage was 300 mg\/m<jats:sup>2<\/jats:sup> (range, 200 to 300 mg\/m<jats:sup>2<\/jats:sup>). The median interval between carboplatin administration and the postchemotherapy CBC was 10 days (range, 6 to 38 days). Eleven dogs developed a grade 2 or higher neutropenia, with 5 dogs developing multiple neutropenic events, for a total of 18 separate events (18\/394). Only 2 of 18 neutropenic events were recorded at the 10- to 14-day postchemotherapy CBC. The yield of detecting neutropenia at a postchemotherapy CBC at any carboplatin chemotherapy after the second dose was &lt; 1% (1\/149). Dogs that developed neutropenia at the pre-2nd chemotherapy CBC had a significantly higher risk of developing another neutropenic event at subsequent prechemotherapy CBC (<jats:italic>P<\/jats:italic> &lt; .001).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>CLINICAL RELEVANCE<\/jats:title>\n<jats:p>The incidence of cumulative neutropenia after 4 to 6 doses of carboplatin is low in cancer-bearing dogs. If a grade 2 or higher neutropenia is observed at or before the second prechemotherapy CBC, the dog is at a higher risk of developing neutropenia following future treatments.<\/jats:p>\n<\/jats:sec>","DOI":"10.2460\/javma.24.02.0109","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T20:12:05Z","timestamp":1721419925000},"page":"1-7","source":"Crossref","is-referenced-by-count":4,"title":["Retrospective analysis of carboplatin-induced cumulative neutropenia in cancer-bearing dogs"],"prefix":"10.2460","volume":"262","author":[{"given":"Vivian","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Delport-Reynolds","sequence":"additional","affiliation":[{"name":"Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"MacDonald-Dickinson","sequence":"additional","affiliation":[{"name":"Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arata","family":"Matsuyama","sequence":"additional","affiliation":[{"name":"Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"issue":"2","key":"ref1","series-title":"J Vet Intern Med","first-page":"76","article-title":"Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993)","volume":"10","author":"Bergman PJ","year":"1996","unstructured":"Bergman PJ, MacEwen EG, Kurzman ID,  Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med. 1996;10(2):76-81. doi:10.1111\/j.1939-1676.1996.tb02031.x"},{"issue":"1","key":"ref2","series-title":"J Vet Intern Med","first-page":"261","article-title":"Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs","volume":"29","author":"Allstadt SD","year":"2015","unstructured":"Allstadt SD, Rodriguez CO Jr, Boostrom B, Rebhun RB, Skorupski KA. Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs. J Vet Intern Med. 2015;29(1):261-267. doi:10.1111\/jvim.12533"},{"issue":"1","key":"ref3","series-title":"Vet Comp Oncol","first-page":"16","article-title":"Piroxicam and carboplatin as a combination treatment of canine oral non-tonsillar squamous cell carcinoma: a pilot study and a literature review of a canine model of human head and neck squamous cell carcinoma","volume":"3","author":"de Vos JP","year":"2005","unstructured":"de Vos JP, Burm AGD, Focker AP, Boschloo H, Karsijns M, van der Waal I. Piroxicam and carboplatin as a combination treatment of canine oral non-tonsillar squamous cell carcinoma: a pilot study and a literature review of a canine model of human head and neck squamous cell carcinoma. Vet Comp Oncol. 2005;3(1):16-24. doi:10.1111\/j.1476-5810.2005.00065.x"},{"issue":"1","key":"ref4","series-title":"Vet Comp Oncol","first-page":"67","article-title":"Evaluation of adjuvant carboplatin chemotherapy in the management of surgically excised anal sac apocrine gland adenocarcinoma in dogs","volume":"14","author":"Wouda RM","year":"2016","unstructured":"Wouda RM, Borrego J, Keuler NS, Stein T. Evaluation of adjuvant carboplatin chemotherapy in the management of surgically excised anal sac apocrine gland adenocarcinoma in dogs. Vet Comp Oncol. 2016;14(1):67-80. doi:10.1111\/vco.12068"},{"issue":"1","key":"ref5","series-title":"Vet Comp Oncol","first-page":"304","article-title":"Clinical presentation, treatment and outcome of canine malignant mesothelioma: a retrospective study of 34 cases","volume":"20","author":"Moberg HL","year":"2022","unstructured":"Moberg HL, Gramer I, Schofield I,  Clinical presentation, treatment and outcome of canine malignant mesothelioma: a retrospective study of 34 cases. Vet Comp Oncol. 2022;20(1):304-312. doi:10.1111\/vco.12777"},{"issue":"1","key":"ref6","series-title":"J Vet Intern Med","first-page":"130","article-title":"Combined gemcitabine and carboplatin therapy for carcinomas in dogs","volume":"23","author":"Dominguez PA","year":"2009","unstructured":"Dominguez PA, Dervisis NG, Cadile CD, Sarbu L, Kitchell BE. Combined gemcitabine and carboplatin therapy for carcinomas in dogs. J Vet Intern Med. 2009;23(1):130-137. doi:10.1111\/j.1939-1676.2008.0248.x"},{"key":"ref7","series-title":"Withrow and MacEwen\u2019s Small Animal Clinical Oncology","first-page":"196","article-title":"Cancer chemotherapy","author":"Gustafson DL","year":"2020","unstructured":"Gustafson DL, Bailey DB. Cancer chemotherapy. In: Vail DM, Thamm DH, Liptak JM, eds. Withrow and MacEwen\u2019s Small Animal Clinical Oncology. 6th ed. Elsevier; 2020:196."},{"issue":"2","key":"ref8","series-title":"Vet Comp Oncol","first-page":"124","article-title":"Inductively coupled plasma mass-spectrometric determination of platinum in excretion products of client-owned pet dogs","volume":"13","author":"Janssens T","year":"2015","unstructured":"Janssens T, Brouwers EEM, de Vos JP, de Vries N, Schellens JHM, Beijnen JH. Inductively coupled plasma mass-spectrometric determination of platinum in excretion products of client-owned pet dogs. Vet Comp Oncol. 2015;13(2):124-132. doi:10.1111\/vco.12025"},{"issue":"11","key":"ref9","series-title":"J Clin Oncol","first-page":"1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert AH","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA,  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748-1756. doi:10.1200\/JCO.1989.7.11.1748"},{"issue":"11","key":"ref10","series-title":"Am J Vet Res","first-page":"1502","article-title":"Effect of glomerular filtration rate on clearance and myelotoxicity of carboplatin in cats with tumors","volume":"65","author":"Bailey DB","year":"2004","unstructured":"Bailey DB, Rassnick KM, Erb HN, Dykes NL, Hoopes PJ, Page RL. Effect of glomerular filtration rate on clearance and myelotoxicity of carboplatin in cats with tumors. Am J Vet Res. 2004;65(11):1502-1507. doi:10.2460\/ajvr.2004.65.1502"},{"issue":"6","key":"ref11","series-title":"Am J Vet Res","first-page":"770","article-title":"Phase I evaluation of carboplatin by use of a dosing strategy based on a targeted area under the platinum concentration-versus-time curve and individual glomerular filtration rate in cats with tumors","volume":"70","author":"Bailey DB","year":"2009","unstructured":"Bailey DB, Rassnick KM, Dykes NL, Pendyala L. Phase I evaluation of carboplatin by use of a dosing strategy based on a targeted area under the platinum concentration-versus-time curve and individual glomerular filtration rate in cats with tumors. Am J Vet Res. 2009;70(6):770-776. doi:10.2460\/ajvr.70.6.770"},{"issue":"4","key":"ref12","series-title":"J Vet Intern Med","first-page":"235","article-title":"Pharmacokinetic and phase I evaluation of carboplatin in dogs","volume":"7","author":"Page RL","year":"1993","unstructured":"Page RL, McEntee MC, George SL,  Pharmacokinetic and phase I evaluation of carboplatin in dogs. J Vet Intern Med. 1993;7(4):235-240. doi:10.1111\/j.1939-1676.1993.tb01013.x"},{"issue":"4","key":"ref13","series-title":"Vet Comp Oncol","first-page":"266","article-title":"Evaluation of factors associated with prolonged hospital stay and outcome of febrile neutropenic patients receiving chemotherapy: 70 cases (1997-2010)","volume":"12","author":"Britton BM","year":"2014","unstructured":"Britton BM, Kelleher ME, Gregor TP, Sorenmo KU. Evaluation of factors associated with prolonged hospital stay and outcome of febrile neutropenic patients receiving chemotherapy: 70 cases (1997-2010). Vet Comp Oncol. 2014;12(4):266-276. doi:10.1111\/vco.12001"},{"issue":"1","key":"ref14","series-title":"Vet Comp Oncol","first-page":"81","article-title":"Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial","volume":"14","author":"Skorupski KA","year":"2016","unstructured":"Skorupski KA, Uhl JM, Szivek A, Allstadt Frazier SD, Rebhun RB, Rodriguez CO Jr. Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial. Vet Comp Oncol. 2016;14(1):81-87. doi:10.1111\/vco.12069"},{"issue":"1","key":"ref15","series-title":"Vet Comp Oncol","first-page":"78","article-title":"Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision","volume":"12","author":"Dank G","year":"2014","unstructured":"Dank G, Rassnick KM, Sokolovsky Y,  Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision. Vet Comp Oncol. 2014;12(1):78-84. doi:10.1111\/j.1476-5829.2012.00338.x"},{"issue":"2","key":"ref16","series-title":"Vet Comp Oncol","first-page":"311","article-title":"Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats","volume":"19","author":"LeBlanc AK","year":"2021","unstructured":"LeBlanc AK, Atherton M, Bentley RT,  Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats. Vet Comp Oncol. 2021;19(2):311-352. doi:10.1111\/vco.12677"},{"issue":"2","key":"ref17","series-title":"Gynecol Oncol","first-page":"592","article-title":"Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy","volume":"92","author":"Markman J","year":"2004","unstructured":"Markman J, Zanotti K, Webster K,  Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy. Gynecol Oncol. 2004;92(2):592-595. doi:10.1016\/j.ygyno.2003.11.005"},{"issue":"1","key":"ref18","series-title":"J Natl Compr Canc Netw","first-page":"99","article-title":"Impact of chemotherapy dose intensity on cancer patient outcomes","volume":"7","author":"Lyman GH","year":"2009","unstructured":"Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw. 2009;7(1):99-108. doi:10.6004\/jnccn.2009.0009"},{"issue":"9","key":"ref19","series-title":"Oncologist","first-page":"e1609","article-title":"Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis","volume":"26","author":"Nielson CM","year":"2021","unstructured":"Nielson CM, Bylsma LC, Fryzek JP, Saad HA, Crawford J. Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis. Oncologist. 2021;26(9):e1609-e1618. doi:10.1002\/onco.13822"},{"issue":"4","key":"ref20","series-title":"Vet Comp Oncol","first-page":"804","article-title":"Carboplatin-induced myelosuppression as related to body weight in dogs","volume":"18","author":"Coffee C","year":"2020","unstructured":"Coffee C, Roush JK, Higginbotham ML. Carboplatin-induced myelosuppression as related to body weight in dogs. Vet Comp Oncol. 2020;18(4):804-810. doi:10.1111\/vco.12622"},{"issue":"5","key":"ref21","series-title":"J Vet Intern Med","first-page":"279","article-title":"Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder","volume":"11","author":"Chun R","year":"1997","unstructured":"Chun R, Knapp DW, Widmer WR,  Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med. 1997;11(5):279-283. doi:10.1111\/j.1939-1676.1997.tb00465.x"},{"issue":"2","key":"ref22","series-title":"J Am Vet Med Assoc","first-page":"195","article-title":"Predictors of outcome in dogs treated with adjuvant carboplatin for appendicular osteosarcoma: 65 cases (1996-2006)","volume":"238","author":"Saam DE","year":"2011","unstructured":"Saam DE, Liptak JM, Stalker MJ, Chun R. Predictors of outcome in dogs treated with adjuvant carboplatin for appendicular osteosarcoma: 65 cases (1996-2006). J Am Vet Med Assoc. 2011;238(2):195-206. doi:10.2460\/javma.238.2.195"},{"issue":"2","key":"ref23","series-title":"J Vet Intern Med","first-page":"554","article-title":"Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma","volume":"28","author":"Selmic LE","year":"2014","unstructured":"Selmic LE, Burton JH, Thamm DH, Withrow SJ, Lana SE. Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma. J Vet Intern Med. 2014;28(2):554-563. doi:10.1111\/jvim.12313"},{"key":"ref24","article-title":"WSAVA Global Nutrition Committee","author":"Body condition score","unstructured":"Body condition score. WSAVA Global Nutrition Committee. Accessed January 24, 2024. https:\/\/wsava.org\/wp-content\/uploads\/2020\/01\/Body-Condition-Score-Dog.pdf"},{"issue":"5","key":"ref25","series-title":"Vet Clin North Am Small Anim Pract","first-page":"883","article-title":"Antimicrobial use in the veterinary cancer patient","volume":"44","author":"Boudreaux B","year":"2014","unstructured":"Boudreaux B. Antimicrobial use in the veterinary cancer patient. Vet Clin North Am Small Anim Pract. 2014;44(5):883-891. doi:10.1016\/j.cvsm.2014.05.004"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/262\/11\/javma.24.02.0109.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/262\/11\/javma.24.02.0109.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/262\/11\/javma.24.02.0109.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T13:10:11Z","timestamp":1741353011000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/262\/11\/javma.24.02.0109.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":25,"journal-issue":{"issue":"11"},"URL":"https:\/\/doi.org\/10.2460\/javma.24.02.0109","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}